Silence Therapeutics plc

Silence Therapeutics plc (SLN) shows zero cyber incidents and zero material red-flag 8-K filings in our 90-day monitoring window, suggesting recent operational stability. However, low signal in a short timeframe does not rule out structural risks—the biotech sector carries inherent dilution exposure and financing volatility that require deeper historical context. The full $49 Report extends analysis back 12 months, adds dilution risk scoring, maps financing history, and flags AI-detected risk signals that may not surface in headline filings. The full $49 Report adds quantified dilution trajectory, multi-year 8-K context, and AI risk signals.